300 Shire Way
Tel: 617 349 0200
About Shire Pharmaceuticals
There’s a simple purpose that sits at the heart of our business: to enable people with life-altering conditions to lead better lives. This means we focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients.
Our growth strategy is to focus on developing and marketing innovative specialty medicines for symptomatic conditions to meet significant unmet patient needs. Our two strategic priorities are to drive optimum performance of our existing products, enabling access to these medicines for patients today; and building our pipeline through research and development (R&D) and business development (BD), delivering access in the future for patients We are always looking for talented people to join the Shire team.
To learn more about Shire, visit www.shire.com.
For more information on career opportunities with Shire, please visit: www.TimeToBeBrave.com .
Shire. To be as brave as the people we help.
367 articles about Shire Pharmaceuticals
Shire R&D Day Profiles Innovative Pipeline Expected To Contribute $3 Billion In Product Sales By 2020
Shire Release: Phase 3 Guanfacine Hydrochloride Extended Release (GXR) Study Shows Improvement In Core Symptoms Of Attention-Deficit/Hyperactivity Disorder (ADHD) In Children And Adolescents
Here’s What An AbbVie-Shire Split Might Mean For Massachusetts
The Reason Why Shire Is Moving Its HQ From Ireland To The U.K.
AbbVie Sued By Louisiana Pension Fund Over $54.5 Billion Shire Pharmaceuticals Deal
Shire Announces Award Recipients For 2014 Michael Yasick ADHD Scholarship
Shire Delivers Record Quarterly Revenues And Non GAAP Diluted Earnings Per ADS Up 42%.
Federal Trade Commission Urged To Probe Shire, Sanofi (France) & Icahn Med School Over A "Conspiracy"
Shire Pharmaceuticals Release: Vyvanse® Patents Found To Be Infringed And Valid By U.S. District Court
Shire plc Release: The Path To US$10 Billion In Product Sales By 2020
Shire plc Release: Management Spurns Three Offers From AbbVie , Fighting For Irish Independence, Call Monday Morning
AbbVie Release: Shire Bid Could Move A Lot High Risk Puts Ceiling At £55/Share
Shire Pharmaceuticals To Participate At The Goldman, Sachs & Co. 35th Annual Global Healthcare Conference
Shire Pharmaceuticals's Best Takeover Defense Is Deal Offense
arGEN-X Inks Long-Term Alliance With Shire Pharmaceuticals Worth $20.4 Million
Shire Pharmaceuticals To Present At The Jefferies and Co. 2014 Global Healthcare Conference
Shire Plans To Submit A New Drug Application To FDA For Lifitegrast For Dry Eye Disease In Adults
Shire Pharmaceuticals To Acquire Lumena Pharmaceuticals For Upfront Payment Of $260 Million In Cash
Shire Delivers A Strong Start To 2014 And Increases Full Year Guidance
Shire Announces The Organize Your Stuff Contest